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Malaria and dengue are two of the most common vector-borne diseases in the world, but
co-infection is rarely described, and immunologic comparisons of co-infection with mono-
infection are lacking.
Methodology and Principal Findings
We collected symptom histories and blood specimens from subjects in a febrile illness
surveillance study conducted in Iquitos and Puerto Maldonado, Peru, between 2002–
2011. Nineteen symptoms and 18 immune markers at presentation were compared
among those with co-infection with Plasmodium/dengue virus (DENV), Plasmodium
mono-infection, and DENV mono-infection. Seventeen subjects were identified as having
Plasmodium/DENV co-infection and were retrospectively matched with 51 DENV mono-
infected and 44 Plasmodiummono-infected subjects. Those with Plasmodiummono-
infection had higher levels of IL-4, IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-γ, and MIP1-α/
CCL3 compared with DENV mono-infection or co-infection; those with Plasmodium
mono-infection had more cough than those with DENV mono-infection. Subjects with
DENV mono-infection had higher levels of TGF-β1 and more myalgia than those with
Plasmodiummono-infection. No symptom was more common and no immune marker
level was higher in the co-infected group, which had similar findings to the DENV mono-
infected subjects.
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Conclusions/Significance
Compared with mono-infection with either pathogen, Plasmodium/DENV co-infection was
not associated with worse disease and resembled DENVmono-infection in both symptom
frequency and immune marker level.
Author Summary
Dengue and malaria are two of the most important diseases spread by mosquitoes. Clinical
manifestations of both febrile diseases overlap considerably, and either can be fatal. In
addition, they are co-endemic in many places throughout the world. Despite this, only a
handful of reports of co-infection with dengue virus and Plasmodium species are reported
in the literature. Through our febrile surveillance program in the Peruvian Amazon, we
were able to retrospectively identify 17 cases of co-infection with dengue virus and Plasmo-
dium. Our study aimed to assess whether co-infection was associated with more symptoms
or a different immune response compared with mono-infection alone. To answer this
question, we utilized data and blood specimens collected during the acute presentation of
these 17 subjects and compared them to a matched group of subjects with either dengue
virus mono-infection or Plasmodiummono-infection. Our findings indicate co-infection
with both pathogens was not associated with more symptoms and the immune profile of
co-infection resembled dengue virus mono-infection more than Plasmodiummono-
infection.
Introduction
Malaria and dengue fever are two of the most important mosquito-borne infections affecting
humans. Annually, approximately 584,000 and 12,000 people die and another 198 million and
96 million are estimated to fall ill from malaria and dengue, respectively [1, 2]. Although
Anopheles, the mosquito vector of malaria, and Aedes, the mosquito vector of dengue virus
(DENV), occupy different ecological niches, considerable geographical overlap in disease risk
exists for the 3.3 and 4.0 billion people who live in an area endemic for malaria and dengue,
respectively [2, 3]. The two diseases also share many common clinical features—including
fever, headache, body aches, and fatigue—making one disease easily mistaken for the other.
Limited availability of diagnostics may be a reason only a handful of reports describe infec-
tion with Plasmodium species (which will be abbreviated Plasmodium) and DENV each year
(Table 1) [4–34]. The first reports of co-infection occurred in 2005 [4, 6] and most subsequent
reports describe only individual patients and rely on serological methods for diagnosing
DENV infection. The majority originate from India and nearby Pakistan, although West Africa
[6], French Guiana [11, 17], Brazil [19, 23, 27], Malaysia [25], Bangladesh [33, 34], East Timor
[9], Thailand [26], and Indonesia [24] have also been the origin of case reports.
The immune responses against DENV and Plasmodium parasites are unique and complex,
although similarities between the two responses exist [35, 36]. Both pathogens elicit a robust
antibody response with the ability to neutralize receptor-mediated invasion of host cells [36,
37]. In addition, DENV and Plasmodium possess pattern recognition molecules which induce
the release of inflammatory molecules, including interleukin (IL)-1β, IL-6, IL-8 and tumor
necrosis factor alpha (TNF-α) [36, 37]. Because both DENV and Plasmodium are intracellular
pathogens, the induction of Th1 cytokines (e.g., IL-2, IL-12 and gamma interferon [IFN]-γ) is
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Table 1. Case reports and case series of co-infection with Plasmodium and dengue virus.



















1 Pf microscopy 3 culture, IgM NR
Bhalla 2006 India 1 Pf microscopy NR IgM No
Ali 2006 Pakistan 9 Pf = 1Pv = 8 microscopy NR IgM Yes One death occurred in the
only Pf-infected subject
Deresinski 2006 India 1 Pv microscopy NR IgM No




Thangaratham 2006 India 1 Pv microscopy 2 culture, IgM No
Kaushik 2007 India 1 Pf & Pv microscopy,
RDT
NR IgM No Three pathogens: DENV,
Pf, and Pv






Chaudhry 2009 India 1 Pv microscopy NR IgM No Four pathogens: DENV,
hepatitis E virus, Leptospira
sp, and Pv
Chander 2009 India 1 Pf microscopy NR IgM No
Carme 2009 French
Guiana
17 Pf = 3Pv = 14 microscopy 1,3 culture,
IgM, PCR
No
Santana 2010 Brazil 2 Pv microscopy 2 culture,
PCR
NR
Magalhães 2012 Brazil 11 Pv microscopy,
PCR




104 Pf = 21,
Pv = 80, Pf &
Pv = 3
microscopy 1,2,3 IgA, IgM,
NS1, PCR











Mohapatra 2012 India 27 Pf = 24,
Pv = 2, Pf &
Pv = 1
microscopy NR IgM, NS1 No Co-infection much more like
dengue than malaria
Hati 2012 India 46 Pf = 18,
Pv = 28
microscopy NR IgM No Co-infection more common
during certain times of the
year
Malhotra 2012 India 1 Pv microscopy,
RDT
NR IgM, NS1 No
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critical for the activation of macrophages, cytotoxic T cells, and other cellular-mediated mecha-
nisms involved in controlling replication of the pathogens. In contrast, the up-regulation of
Th2 cytokines (e.g., IL-4, IL-5, and IL-13) and regulatory cytokines (e.g., IL-10 and transform-
ing growth factor [TGF]-β1) is associated with immune escape and disease progression follow-
ing DENV or Plasmodium infection [38].
Despite the need for the activation of inflammatory responses during the development of
protective immunity, activation of these pathways may also result in tissue damage and severe
disease [35, 36, 39]. Several of the pro-inflammatory cytokines induced by DENV or Plasmo-
dium, such as IL-6, TNF-α, and IL-1β, are important mediators of acute phase proteins, as well
as mechanisms of endothelial cell activation and secretion of chemokines. These molecules
contribute to increased vascular permeability during severe dengue or are associated with
sequestration of parasitized red blood cells during severe malaria, particularly cerebral malaria.
Conversely, the induction of regulatory cytokines such as IL-10 has been involved in protection
from severe disease in both dengue and malaria. Thus, the modulation of the inflammatory
response following DENV or Plasmodium infection likely influences the onset of symptoms
Table 1. (Continued)















Mushtaq 2013 India 1 Pf & Pv microscopy,
RDT
NR IgM No Three pathogens: DENV,
Pf, and Pv
Yong 2013 Malaysia 1 Pv microscopy NR IgM No Three pathogens: DENV,
Leptospira sp, and Pv





Assir 2013 Pakistan 17 Pf = 3, Pv = 14 microscopy NR IgM, NS1,
PCR




with Plasmodium or DENV
than with co-infection
Pande 2013 India 1 Pf & Pv microscopy,
RDT
NR IgM, NS1 No Three pathogens: DENV,
Pf, and PvPregnant




No Co-infection had more
jaundice, hepatomegaly,
and severe disease than
dengue; co-infection had
more bleeding than malaria
Satyawali 2014 India 1 Pf microscopy,
RDT
NR IgM, NS1 No Three pathogens: DENV,
Pf, Wuchereria bancrofti
Issaranggoon 2014 Thailand 1 Pf microscopy NR IgM, NS1 No
Kumar 2014 India 1 Pv microscopy,
RDT
NR IgM, NS1 No Three pathogens: DENV,
Orientia tsutsugamushi, and
Pv
Bhagat 2014 India 3 Pv microscopy,
RDT
NR IgM, NS1 No
Swoboda 2014 Bangladesh 19 NR microscopy,
RDT
NR IgM NR One also had typhoid fever
and 13 also had
leptospirosis
DENV: dengue virus; Pf: Plasmodium falciparum; Pv: Plasmodium vivax; NR: not reported; ICT: immunochromatographic test; NS1: dengue antigen NS1;
PCR: polymerase chain reaction; RDT: rapid diagnostic test
doi:10.1371/journal.pntd.0004646.t001
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and disease outcome. Because DENV and Plasmodium both induce a type-1 immune response,
co-infection theoretically could result in either enhanced pathogen clearance or increased
immunopathogenesis. Given the overlapping endemicities of these two infections, it is impor-
tant to understand the immune interactions that occur during co-infection, as they may lead to
improved management of such cases or the identification of biomarkers to better identify co-
infected cases.
To characterize symptoms and immune marker secretion profile associated with Plasmo-
dium/DENV co-infection, we conducted an exploratory, retrospective comparative study in
which we identified 17 cases with Plasmodium/DENV co-infection and matched Plasmodium
and DENV mono-infected controls. These cases were identified through a febrile surveillance




This study utilized institutional review board (IRB)-approved protocols 2000.0006 (U.S. Naval
Medical Research Center; Silver Spring, MD), 2010.0010 (U.S. Naval Medical Research Unit
No. 6 (NAMRU-6); Lima, Peru), and 2012.0002 (NAMRU-6), in compliance with all U.S. Fed-
eral regulations governing the protection of human subjects. Protocols 2000.0006 and
2010.0010 were also reviewed by the Peruvian Ministry of Health. After being informed of the
study, written consent was obtained from all participating adults or a parent or legal guardian
of subjects 5–17 years old. Assent was also obtained from subjects between ages 8–17 years old.
Protocol 2012.0002 covered immune marker testing of the specimens collected in the two
aforementioned protocols.
Patient recruitment
From January 2002 to March 2011, subjects with an undifferentiated febrile illness were
recruited at outpatient clinics and screened for the presence of an arboviral infection, as
described previously [40]. This population is almost entirely formed by Peruvian citizens of
mestizo origin. For this project, we only included local residents eligible for healthcare in the
Peruvian cities of Iquitos and Puerto Maldonado because the Peruvian Ministry of Health
often screened febrile subjects for malaria in addition to our arboviral assays to detect infection
with DENV. Because the Ministry of Health’s malaria screening was only incorporated into the
febrile surveillance during certain time periods, samples—both mono-infected and co-infected
—were only selected from these time periods. Inclusion criteria for febrile surveillance were: 1)
oral/tympanic temperature> 38.0°C (or axillary> 37.5°C) or report of fever starting within
the previous 5 days, 2) no obvious source of infection such as cellulitis, dental abscess, or uri-
nary tract infection, and 3) age 5 years. Subjects infected with two serotypes of DENV (e.g.,
both DENV-1 and DENV-3) or two species of Plasmodium (e.g., both Plasmodium vivax and
Plasmodium falciparum) were excluded from the analysis.
Collection of symptom data
Each site used a standardized questionnaire which collected the demographic and symptom
information assessed in this study. In addition, all participating healthcare personnel received
standardized training in data collection. We assessed 19 symptoms in our analysis: abdominal
pain, nausea, vomiting, diarrhea, rhinorrhea, cough, expectoration, epistaxis, bleeding gums,
Plasmodium/Dengue Co-infection versus Mono-infection
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hematuria, hematochezia, prostration, asthenia, chills, malaise, arthralgia, myalgia, eye pain,
and headache.
Laboratory determination of DENV and Plasmodium infection
Both a 10 ml serum and a 2 ml whole blood sample were collected from febrile subjects.
Microscopy was the primary method of identifying Plasmodium and culture was the primary
method of identifying DENV, but DENV and Plasmodium-specific polymerase chain reaction
(PCR) were used to augment these modalities when sufficient sample was available, as will be
discussed later in this paragraph. A portion of the whole blood sample was used for malaria
microscopy, performed at the site of collection by the Peruvian Ministry of Health using thick
and thin smears according to national guidelines [41]. The remainder of the whole blood sam-
ple and the serum sample were stored at -80°C until transfer to NAMRU-6 on dry ice. At
NAMRU-6, if sufficient quantity of whole blood existed, the infecting Plasmodium species was
confirmed by PCR [42] on samples deemed positive by smear; Plasmodium PCR was also used
to further rule out the presence of Plasmodium in smear-negative, DENV-positive specimens.
To assess for the presence of DENV, serum was inoculated on C6/36 and Vero cell cultures, as
previously described [40]. After ten days or upon appearance of cytopathic effect, immunofluo-
rescent antibodies to a wide range of endemic arboviruses, including the four DENV serotypes,
were added. PCR for DENV was also performed on a subset of samples, as previously described
[40]. Primary versus secondary DENV infection was determined using a ratio of enzyme linked
immunosorbent assay (ELISA) titers for IgM and IgG, similar to an approach used by others
[43].
Classification/selection of co-infected and mono-infected cases
A subject was determined to be mono-infected with Plasmodium if they had a positive malaria
smear and a negative viral culture and ELISA IgM for DENV. A subject was determined to be
mono-infected with DENV if they had a positive culture or PCR for DENV and negative
malaria microscopy (and PCR, if sufficient quantity of whole blood existed). A subject was
determined to be co-infected if both a DENV assay (culture or PCR) and malaria microscopy
were positive.
First, we identified all co-infections from the two study sites in the project database. We
then selected three DENV mono-infected subjects and two to three Plasmodiummono-
infected subjects for each co-infected subject (two co-infected subjects did not have Plasmo-
diummono-infected controls) to compare symptom frequency and levels of immune markers.
All mono-infected control subjects were individually matched to a co-infected case by recruit-
ment site, time of enrollment (±3 months), gender, and DENV serotype. Pregnant subjects
were excluded from analysis due to the difficulty in finding adequately matched control
subjects.
Measurement of immune markers
Serum immune marker levels were measured using the xMAP platform (Luminex; Austin,
TX), following the manufacturer’s recommendations. A 10-point calibration curve was used
instead of an 8-point calibration curve to improve performance at the lower range of detection.
The reactions were detected using the Bio-plex 100 (Bio-Rad Laboratories; Hercules, CA) sys-
tem, and cytokine, chemokine, and growth factor concentrations were calculated using Bio-
plex Manager Software (Bio-Rad Laboratories). The limit of detection (LOD) was defined as
the lowest calibrator value at which the coefficient of variance of concentration was less than
25% and recovery of calibrator was within 20% of the expected value. All values below the LOD
Plasmodium/Dengue Co-infection versus Mono-infection
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were considered undetectable and assigned a value equal to half the plate-specific LOD. TGF-
β1 was detected using a commercially available ELISA assay (R&D Systems; Minneapolis,
MN). The 18 immune markers tested belonged to the following categories: inflammatory acute
response cytokines (IL-1β, IL-6, IL-8, TNF-α); chemokines and growth factors (IL-2, IL-7,
granulocyte colony stimulating factor [G-CSF], monocyte chemoattractant protein [MCP]-1/
CCL2, macrophage inflammatory protein [MIP]-1α/CCL3); inflammatory Th1 cytokines (IL-
12, IFN-γ); inflammatory Th2 cytokines (IL-4, IL-5, IL-13); inflammatory Th17 cytokines (IL-
17A, granulocyte macrophage colony stimulating factor [GM-CSF]); and regulatory cytokines
(IL-10, TGF-β1). For IL-12, the assay detected the p70 protein; therefore, our assay was specific
for IL-12 and did not cross-react with IL-23. All samples were tested in the same batch under
the same conditions. Immune markers with values undetectable in more than 75% of the sam-
ples were not included in the analysis.
Statistical analysis
Symptom frequencies among the three groups were compared using conditional logistic regres-
sion, using a separate regression to compare the frequency of each individual symptom
between co- and mono-infections. The concentrations of immune markers were compared
among the three groups using the Kruskal-Wallis test, a non-parametric method that is robust
and less affected by outliers. Log-transformed cytokine concentrations were compared between
the three groups using random effects linear regression, again with a separate regression for
each immune marker. Age and number of days with fever, and the influence of other covariates
not matched for in the study design were adjusted in the regression analyses. The sample size
available had 80% power to detect a difference of 0.8 standard deviations in immune marker
levels between co- and mono-infected individuals.
Results
Seventeen co-infected subjects (14 P. vivax and 3 P. falciparum; 2 DENV-1 and 15 DENV-3)
were identified and included in the study (Table 2). Plasmodium infection was initially identi-
fied with microscopy in all subjects and further confirmed with PCR in five (adequate sample
was not available to perform confirmatory PCR on the others). DENV infection was estab-
lished with culture in 15 subjects and with PCR in two subjects. Using the aforementioned
matching criteria, 51 DENV mono-infected subjects and 44 Plasmodiummono-infected sub-
jects were selected for comparison. The age distribution was similar among the three groups.
The frequencies of the DENV serotypes were similar between the co-infected and DENV
mono-infected subjects and the frequencies of the Plasmodium species were similar between
the co-infected and Plasmodiummono-infected subjects. The average number of days with
symptoms was lower in DENVmono-infected subjects compared to Plasmodiummono-
infected or co-infected subjects (p<0.05; Table 2).
Only two symptoms were significantly different (p<0.05) upon comparison among the
three groups: 1) more frequent myalgia in DENV mono-infected vs Plasmodiummono-
infected subjects, and 2) more frequent cough in Plasmodiummono-infected vs DENV mono-
infected subjects (Table 3). These differences remained significant after adjusting for age and
days since symptoms onset. No symptoms were significantly more frequent in co-infection
cases. Only two subjects reported epistaxis, one in the co-infected group and one in the DENV
mono-infected group. No subject reported any of the other hemorrhagic manifestations—gum
bleeding, hematochezia, or hematuria.
To examine the immune profile of individuals with co-infection, we compared the concen-
tration of 15 immune markers (IL-1β, IL-6, IL-8, TNF-α, IL-7, G-CSF, MCP-1/CCL2, MIP-1-
Plasmodium/Dengue Co-infection versus Mono-infection
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α/CCL3, IL-12, IFN-γ, IL-13, IL-17A, GM-CSF, IL-10, and TGF-β1) among the three groups
using Kruskal-Wallis ANOVA. Three other immune markers (IL-2, IL-5, and GM-CSF) were
excluded from the analysis given their high frequency of measurements falling below the LOD.
The Plasmodiummono-infected group had significantly (p<0.05) higher concentrations for
the majority of the immune markers tested compared to the DENV mono-infected or the co-
infected groups (Fig 1). The consistently higher levels in Plasmodiummono-infected subjects
were not particular to a specific type of immune marker, as significant differences were found
in the inflammatory acute response (IL-1β, IL-6), chemokine and growth factor (G-CSF), Th1
(IL-12, IFN-γ), Th2 (IL-4), Th17 (IL-17A), and the regulatory cytokine IL-10. In contrast, the
concentration of TGFβ1, a regulatory cytokine, was significantly higher in the DENVmono-
infected group compared to either the Plasmodiummono-infected or co-infected groups.
DENVmono-infected subjects and co-infected subjects had similar levels for all other immune
markers except IL-4 and IL-7, which were both higher in the DENV mono-infected group
compared to the co-infected group. IL-4 was the only immune marker with statistically signifi-
cant differences across the three groups, with the Plasmodiummono-infected group having the
highest and the co-infected group the lowest level (Fig 1). No immune marker was significantly
higher in the co-infected group compared to either of the mono-infected groups.
To assess for the influence of other covariates which were not matched for in the study
design, we fitted a random effects regression model for matched group analysis, adjusting for
age and number of days with fever. This analysis confirmed the above results in that the Plas-
modiummono-infected subjects had significantly higher serum concentrations of IL-4, IL-6,
IL-10, IL-12, IL-13, IL-17A, MIP-1α/CCL3, and IFN-γ (p< 0.05) than either the co-infected
or the DENVmono-infected subjects (Table 4) even when adjusting for age and the number of
Table 2. Characteristics of the co-infected, dengue virus mono-infected, and Plasmodiummono-infected groups.
Co-infected (n = 17) DENV(n = 51) Plasmodium(n = 44) p value**
Items not matched
Mean age (SD) 29.0 (17.3) 27.8 (13.1) 29.6 (16.1) 0.845
Days of symptoms at presentation (SD) 3.1 (1.7) 2.1 (1.3) 3.1 (1.8) 0.006
DENV infection 0.309
Primary 8 (47%) 17 (33%) N/A
Secondary 9 (53%) 34 (67%) N/A
Malaria species 0.638
P. vivax 14 (82%) N/A 36 (82%)
P. falciparum 3 (18%) N/A 8 (18%)
Items matched*
Gender
male 12 (71%) 36 (71%) 29 (66%)
female 5 (29%) 15 (29%) 15 (34%)
Location
Iquitos 16 (94%) 48 (94%) 44 (100%)
Puerto Maldonado 1 (6%) 3 (6%) 0
DENV serotype
DENV-1 2 (12%) 6 (12%) N/A
DENV-3 15 (88%) 45 (88%) N/A
*Subjects were also matched by date of enrollment (±3 months)
**p values determined using chi square, Fisher's exact, and ANOVA; DENV: dengue virus; SD: standard deviation
doi:10.1371/journal.pntd.0004646.t002
Plasmodium/Dengue Co-infection versus Mono-infection
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004646 April 29, 2016 8 / 16
days. Additionally, TGF-β1 was the only immune marker significantly higher in the DENV
mono-infected subjects than in the Plasmodiummono-infected subjects.
Discussion
This study adds Peru to other South American countries reporting Plasmodium/DENV co-
infection in the Amazon region. Our results revealed a strikingly similar inflammatory profile
between subjects with co-infection and DENV mono-infection, in sharp contrast to the higher
levels of immune markers in those with Plasmodiummono-infection. On the other hand, most
symptoms occurred with similar frequencies between the three groups, although the study was
most likely underpowered to detect differences. Because the Ministry of Health’s malaria
microscopy samples were incorporated into this febrile surveillance protocol only during cer-
tain time periods over the nine-year study, we did not calculate an incidence of Plasmodium/
DENV co-infection for this timeframe.
In addition to this investigation, only five studies of Plasmodium/DENV co-infection have
compared co-infected subjects to those with mono-infection [10, 17, 21, 27, 30]. A study from
Pakistan looking at 19 clinical features found only one to be different in co-infected patients,
jaundice, and this occurred less often in the co-infected group than either Plasmodium or
DENVmono-infection [30]. A group from India followed 27 co-infected, 102 Plasmodium
mono-infected, and 340 DENVmono-infected subjects and compared symptoms and routine
laboratory values, including liver function tests and hematologic parameters [21]. P. falciparum
was the most prevalent malaria species in this study, although they observed trends similar to
ours where P. vivax predominated. Specifically: 1) similarities between Plasmodium/DENV co-
infection and DENVmono-infection; 2) differences between Plasmodium/DENV co-infection
Table 3. Symptom frequency in subjects with co-infection, dengue virus (DENV) mono-infection, and Plasmodiummono-infection.
Symptoms Co-infection n/total (%) DENV n/total (%) Plasmodium n/total (%) p value*
Abdominal pain 8/17 (47%) 15/51 (29%) 21/44 (48%) 0.1033
Epistaxis*** 1/17 (7%) 1/51 (2%) 0/44 (0%) 0.282
Prostration 2/15 (13%) 2/51 (4%) 3/41 (7%) 0.5625
Asthenia 9/16 (56%) 23/51 (45%) 18/44 (41%) 0.3873
Chills 15/17 (88%) 48/51 (94%) 41/44 (93%) 0.7081
Malaise 15/16 (94%) 50/51 (98%) 41/41 (100%) 0.4286
Pallor 5/16 (31%) 11/51 (22%) 18/44 (41%) 0.2133
Rash 2/16 (13%) 2/51 (4%) 0/41 (0%) 0.0445
Arthralgia 14/16 (88%) 48/51 (94%) 39/44 (87%) 0.4844
Myalgia 13/16 (81%) 45/51 (88%) 30/44 (68%) 0.031**
Diarrhea 4/17 (24%) 7/51 (14%) 7/44 (16%) 0.6376
Nausea 13/17 (76%) 36/51 (71%) 28/44 (64%) 0.4135
Vomiting 8/17 (47%) 23/51 (45%) 16/44 (36%) 0.2949
Rhinorrhea 2/16 (13%) 4/50 (8%) 6/44 (14%) 0.8348
Cough 5/16 (31%) 5/51 (10%) 15/44 (34%) 0.010**
Expectoration 1/16 (6%) 2/51 (4%) 3/44 (7%) 0.8648
Headache 16/16 (100%) 51/51 (100%) 42/44 (95%) 0.1837
Eye pain 10/15 (67%) 40/51 (78%) 28/41 (68%) 0.455
* Conditional logistic regression, matched analyses
** Dengue virus mono-infection different from Plasmodium mono-infection
*** No recorded cases of gum bleeding, hematochezia, or hematuria
doi:10.1371/journal.pntd.0004646.t003
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and Plasmodiummono-infection; and 3) no apparent worsened disease during infection with
both pathogens. Conversely, the largest comparison study of co-infected subjects, which
described 104 co-infected patients in French Guiana, showed that hypotension,
Fig 1. Serum levels of immunemarkers among patients with Plasmodium/DENV co-infection, DENVmono-infection, and Plasmodiummono-
infection. Serum levels were analyzed by 17-plex cytokine array (Biorad Laboratories) for all immune markers except TGF-β1, which was measured by an
R&D Systems ELISA kit. Three immune markers were excluded (GM-CSF, IL-5, and IL-2) from this analysis because more than 25% of the values fell below
the limit of detection of the assays. Horizontal bars represent group median and inter-quartile range. Red dotted lines show lower limit of detection for each
immune marker. Units on the y-axis are log 10 transformed scales of analyte concentration in ng/mL for all immune markers except for TGF-β1, which is
represented in μg/mL. * p<0.05 for group comparison by the Kruskal-Wallis test followed by post-hoc Dunn’s pair-wise comparison.
doi:10.1371/journal.pntd.0004646.g001
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thrombocytopenia, and anemia were more common in co-infection than in mono-infection
with either pathogen alone [17]. Similarly, a study from Brazil showed more bleeding, hepato-
megaly, and jaundice in the co-infected group [27]. Furthermore, a study from Pakistan
contrasted 26 co-infected subjects with 52 DENV mono-infected subjects and found that
hematocrit, hemoglobin, and platelet levels were all lower in the co-infected group although
leukopenia was more common in those with DENV mono-infection [10]. However, symptoms
were not compared, tests of statistical significance were not performed, and no attempt was
made to match or adjust the comparator groups for other covariates. The differences in the
findings among these five studies and ours—with three demonstrating and three not demon-
strating worse disease in co-infected subjects—may be due to differences in DENV serotypes,
Plasmodium species, or outcomes evaluated.
While tempting to hypothesize that Plasmodium/DENV co-infection would routinely result
in more severe outcomes, as seen in the French Guiana study, most co-infection case reports
do not describe severe or fatal outcomes (Table 1). The majority of co-infection cases in the lit-
erature occurred in regions, similar to ours, with a predominance of P. vivax, a malaria species
less associated with severe outcomes than P. falciparum [44]. All case reports describing fatal
or near-fatal Plasmodium/DENV co-infection involved P. falciparum, including those from
West Africa [6], Indonesia [24], East Timor [9], Pakistan [7], and India [16]. Nevertheless,
Table 4. Matched group comparisons of inflammatory marker levels in subjects with co-infection, dengue virusmono-infection, and Plasmodium
mono-infection using random effect regression.
Immune marker Median (Interquartile Range)
Co-infection (n = 17) Dengue virus (n = 51) Plasmodium (n = 44) p-value*
Acute phase proteins
IL-1β 0.8 (0.3–1.1) 0.7 (0.3–1.0) 1.4 (0.7–2.2) <0.001#
IL-6 17.1 (5.8–27.0) 15.6 (7.8–23.3) 50.4 (18.9–188.2) <0.001¶, #
TNFα 6.5 (2.6–32.4) 8.6 (4.8–19.7) 11.9 (4.8–24.3) 0.82
IL-8 17.7 (12.7–27.2) 21.7 (13.8–30.1) 19.4 (13.6–32.5) 0.85
Chemokines and growth factors
MCP1/CCL2 176.3 (113.7–294.5) 221.2 (109.3–408.1) 160.0 (55.3–386.2) 0.07
MIP1α/CCL3 292.3 (210.2–400.6) 295.2 (242.2–421.0) 362.3 (248.1–526.3) 0.043¶, #
G-CSF 18.21 (7.2–31.9) 18.2 (12.3–25.9) 38.0 (21.6–66.3) 0.091#
IL-7 6.5 (3.6–8.6) 9.0 (6.5–11.8) 8.2 (5.1–12.6) 0.04
Th1
IL-12p40 22.8 (12.9–28.1) 20.9 (15.7–28.5) 34.1 (23.2–53.1) 0.002¶, #
IFNγ 9.6 (1.0–76.3) 17.1 (7.2–34.5) 56.7 (22.1–128.3) 0.001¶, #
Th2
IL-4 0.4 (0.1–1.1) 0.8 (0.5–1.4) 2.2 (0.8–3.7) <0.001¶, #
IL-13 1.2 (0.3–3.9) 0.9 (0.3–3.1) 3.5 (1.0–8.2) 0.010¶, #
Th17
IL-17A 21.2 (10.4–40.2) 27.1 (14.8–35.6) 42.3 (21.3–62.8) 0.008¶, #
Regulatory cytokines
IL-10 18.6 (2.1–66.4) 11.7 (6.2–22.8) 77.8 (18.7–475.4) <0.001¶, #
TGFβ1 7.9 (2.3–14.6) 12.6 (8.2–19.6) 7.7 (2.1–10.2) 0.017#
*Overall comparison across all three groups using a mixed-random effect regression model after adjusting for patient age and number of days with fever
¶ p < 0.05 when comparing co-infected and Plasmodium mono-infected groups in the model
# p < 0.05 when comparing Plasmodium mono-infected and dengue virus mono-infected groups in the model
doi:10.1371/journal.pntd.0004646.t004
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severe manifestations are still possible when Plasmodium/DENV co-infection occurs with P.
vivax, as demonstrated in the larger studies from French Guiana and Brazil [17, 27].
Both malaria and dengue have been associated with a strong activation of acute phase
response (IL-6, TNF-α, and IL1-β) and Th1 cytokines (IFN-γ and IL-12). Therefore, we
hypothesized that co-infection may result in synergistic activation of these pathways and over-
all higher levels of pro-inflammatory immune markers in the serum. However, our compre-
hensive characterization of multiple cytokines, chemokines, and growth factors using a highly
sensitive multiplex platform revealed that Plasmodiummono-infected subjects had higher lev-
els of many of the immune markers evaluated compared to DENV mono-infected subjects
even after matching and adjusting for other covariates. The lower levels of inflammation in the
co-infected group were, in fact, similar to DENV mono-infected subjects. Consistent with our
results, P. falciparum infection has been associated with a greater activation of inflammatory
response compared with DENV infection, including higher levels of IFN-γ and IL-10 [45] and,
in some cases, P. vivaxmay have an even more robust inflammatory response than P. falcipa-
rum [46].
The regulatory marker TGF-β1 was the only immune marker with higher levels in DENV
mono-infected individuals compared to Plasmodiummono-infected and co-infected subjects.
Prior studies of TGF-β1 in DENV mono-infection have demonstrated a positive correlation
with symptomatic disease. A group from French Polynesia showed that TGF-β1 levels were
highest in those with dengue hemorrhagic fever versus dengue fever; likewise, higher levels
were found in those with dengue fever than healthy controls [47]. A study of subjects with den-
gue in India similarly showed a correlation of TGF-β1 levels with severity and also length of
disease [48]. In our study and others, TGF-β1 levels in malaria show an opposite trend com-
pared with dengue. TGF-β1 levels were higher in healthy Tanzanian controls compared to
those with P. falciparummalaria. In the same study, TGF-β1 levels were inversely correlated
with malaria severity [49]. Parasite density in children from Gabon with P. falciparummalaria
was also shown to be inversely related to TGF-β1 levels and highest in those without malaria
[50]. Our findings are consistent with these four studies, which together demonstrate high
TGF-β1 levels in symptomatic dengue and low TGF-β1 levels in symptomatic malaria.
Following infection with DENV, viremia first peaks and then becomes undetectable over a
timespan usually lasting less than three weeks. Chronic infection is not a characteristic of
dengue. Asymptomatic, long-lasting Plasmodium infections, however, are common both in
P. vivax and P. falciparummalaria [51]. In the case of P. vivax, a clinically dormant hypnozoite
form exists that may reactivate months or years later during a physiological stressor, such as
DENV infection. The scenario of acute, symptomatic DENV infection occurring in a person
with clinically silent Plasmodium infection would explain why the immune marker profile of
our co-infected subjects nearly always resembled DENV mono-infected subjects. In contrast,
our subjects with Plasmodiummono-infection most likely presented with fever directly attrib-
utable to malaria and therefore displayed a vastly different immune marker response from the
other two groups. This same reasoning would account for why Plasmodium/DENV co-infec-
tion did not result in a higher frequency of symptoms than mono-infection with DENV. Fur-
ther studies in humans or animal models are needed to better understand the effect of DENV
infection on the course of Plasmodium infection or vice versa.
A few caveats are worth noting. First, given the retrospective nature of our study, we mea-
sured soluble immune marker levels in the serum which are not pathogen-specific, so it is pos-
sible that other infections or underlying medical conditions may have confounded our
findings. However, we individually matched mono-infected subjects to every co-infected sub-
ject in terms of gender, enrollment site, and period (±3 months). In addition, we performed
immune marker testing on all samples at the same time in order to avoid batch variability.
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Second, due to the design of the studies, we did not collect clinical laboratory data, such as
platelet levels, creatinine, liver enzymes, or hematocrit, which can be used to stratify disease
severity and has been utilized to differentiate between Plasmodium and DENVmono-infection
in other studies [52]. Furthermore, we only assessed our subjects at one point in time, which
could have missed evolution to a more severe disease state, such as dengue hemorrhagic fever,
which classically follows an initial, less severe dengue fever stage. However, dengue hemor-
rhagic fever was virtually non-existent in Iquitos and Puerto Maldonado during the time of our
study. Next, our study occurred during a timeframe when DENV-3 and P. vivax were promi-
nent in the study regions and infection with P. falciparum was not associated with severe out-
comes, so our results may not be generalizable to areas in the world with different DENV
serotypes or a predominance of P. falciparummalaria. Finally, our sample size may have been
too small to detect differences in most symptoms; however, large and statistically significant
differences in immune marker levels were still able to be observed, even though the study may
have been underpowered to detect more nuanced differences.
Our results verify the existence of Plasmodium/DENV co-infection in the Amazon region of
Peru. Therefore, diagnosis of one disease in a febrile patient in this area does not preclude
infection with the other. This realization is significant because malaria can be treated with
prompt administration of anti-malarial medications, which could be mistakenly withheld if
only DENV were presumed in a co-infected patient. Although effective anti-viral treatment is
not available for dengue disease, early identification is crucial for the supportive management
of severe cases [53]. For the time period of our study, co-infection did not yield more symp-
toms or higher immune marker levels than mono-infection alone. While this is momentarily
reassuring, the recent discovery of more life-threatening forms of malaria [54] and DENV [55]
in the region emphasize the future importance of not overlooking either of these potentially
fatal but treatable diseases.
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